Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma

2014; Elsevier BV; Volume: 18; Issue: 3 Linguagem: Inglês

10.1016/j.bjid.2014.01.002

1678-4391

Érico Antônio Gomes de Arruda, Alexandre A. Jácome, Ana Luiza de Castro Conde Toscano, Anderson Arantes Silvestrini, André Santa Bárbara Rêgo, Evanius Garcia Wiermann, Geraldo Felicio da Cunha, Heloísa Ramos Lacerda de Melo, Karen Mirna Loro Morejón, Luciano Z. Goldani, Luiz Carlos Pereira, Mariliza Henrique da Silva, Mauro Sergio Treistman, Mônica Cristina Toledo Pereira, Patricia Maria Bezerra Xavier Romero, Rafael Schmerling, Rodrigo Antonio Vieira Guedes, Veridiana Pires de Camargo,

Parvovirus B19 Infection Studies

Kaposi's sarcoma is a multifocal vascular lesion of low-grade potential that is most often present in mucocutaneous sites and usually also affects lymph nodes and visceral organs. The condition may manifest through purplish lesions, flat or raised with an irregular shape, gastrointestinal bleeding due to lesions located in the digestive system, and dyspnea and hemoptysis associated with pulmonary lesions. In the early 1980s, the appearance of several cases of Kaposi's sarcoma in homosexual men was the first alarm about a newly identified epidemic, acquired immunodeficiency syndrome. In 1994, it was finally demonstrated that the presence of a herpes virus associated with Kaposi's sarcoma called HHV-8 or Kaposi's sarcoma herpes virus and its genetic sequence was rapidly deciphered. The prevalence of this virus is very high (about 50%) in some African populations, but stands between 2% and 8% for the entire world population. Kaposi's sarcoma only develops when the immune system is depressed, as in acquired immunodeficiency syndrome, which appears to be associated with a specific variant of the Kaposi's sarcoma herpes virus. There are no treatment guidelines for Kaposi's sarcoma established in Brazil, and thus the Brazilian Society of Clinical Oncology and the Brazilian Society of Infectious Diseases developed the treatment consensus presented here.